Screener
Recursion Pharmaceuticals, Inc. RXRX Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Net cash provided by (used in) financing activities | (4,737) | 138,186 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (3,019) | 14,088 |
| Net change in cash, cash equivalents and restricted cash | (197,101) | (69,179) |
| Cash, cash equivalents and restricted cash, beginning of period | 753,921 | 603,024 |
| Cash, cash equivalents and restricted cash, end of period | $556,820 | $533,845 |
| Supplemental schedule of non-cash investing and financing activities | ||
| Accrued property and equipment | 300 | 263 |
| Purchase of an equity investment | — | 4,438 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s cash, cash equivalents, restricted cash, and restricted cash equivalents?
- Recursion Pharmaceuticals, Inc. (RXRX) reported cash, cash equivalents, restricted cash, and restricted cash equivalents of $556.82M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s cash, cash equivalents, restricted cash, and restricted cash equivalents changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s cash, cash equivalents, restricted cash, and restricted cash equivalents increased by 4.3% year-over-year, from $533.85M to $556.82M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s cash, cash equivalents, restricted cash, and restricted cash equivalents?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s cash, cash equivalents, restricted cash, and restricted cash equivalents has grown at a 23.1% compound annual growth rate (CAGR), from $267.17M to $753.92M.
- What does cash, cash equivalents, restricted cash, and restricted cash equivalents mean?
- Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents as reported by Recursion Pharmaceuticals, Inc. Class A Common Stock.
Ask your AI about Recursion Pharmaceuticals, Inc.'s cash, cash equivalents, restricted cash, and restricted cash equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude